Animals were treated in accordance with the ARVO Statement for
the Use of Animals in Ophthalmic and Vision Research. Eyes or embryo
heads were collected from CD1 mice at embryonic (E) days 10.5, E12.5,
E14.5; and E17.5, postnatal (P) days 1, P4, P7, P10, and P14; and at
adulthood (3 weeks and 2 months), fixed with 2%
paraformaldehyde-lysine-periodate
28 for 4 hours at 4°C,
and cryoprotected in a series of 5%, 10%, 15%, and 20% sucrose in
phosphate-buffered saline for 2, 2, 6, and 16 hours, respectively.
Frozen sections (10-μm-thick) were collected on
poly-
l-lysine–coated slides (Mentzel-Glaser,
Braunschweig, Germany) and incubated with affinity-purified polyclonal
antibody for RARα
29 (diluted 1:2000),
RARβ
30 (1:400), RARγ
31 (1:1000),
RXRα
32 (1:2000), RXRβ
33 (1:1000), or
RXRγ (1:1000, sc555; Santa Cruz, CA) for 16 hours at 4°C. The
immunoreactivity was visualized by incubation with CY3-labeled
anti-rabbit IgG (Chemicon International, Temecula, CA) diluted 1:500
for 1 hour at room temperature. Counterstaining was done with DAPI in
the mounting medium (Vectashield; Vector Laboratories, Burlingame, CA).
Histologic sections from mutant mice carrying targeted inactivation of
RARα,
34 RARβ,
23 RARγ,
35 RXRα,
21 RXRβ,
36 and RXRγ
37 were used as negative controls of the immunostaining procedure as
previously described.
38